Introduction {#Sec1}
============

Smoking is now considered a chronic disease caused by nicotine dependence and is one of the main risk factors for various diseases \[[@CR1]\]. By 2020, annual tobacco-related deaths are projected to increase to 7.5 million, accounting for 10% of all deaths in that year. Smoking is estimated to cause about 71% of all lung cancer deaths, 42% of chronic respiratory disease, and nearly 10% of cardiovascular disease. Smoking is also an important risk factor for communicable diseases such as tuberculosis and lower respiratory infections \[[@CR2]\]. Around 80% of the 1.1 billion smokers worldwide live in low- and middle-income countries, where the burden of tobacco-related illness and death is heaviest \[[@CR3]\].

Cigarette smoking behavior is defined as actively smoking one or more manufactured or hand-rolled cigarettes with the intention to inhale the tobacco smoke \[[@CR4]\]. Smoking is also a social behavior that results in a physical and psychological dependence requiring a specific treatment. The CDC 2011 indicated that70% of smokers would like to quit smoking, and 50% report attempting to quit within the past year \[[@CR5]\]. Nicotine dependence is the major obstacle to the success of quitting \[[@CR6]\].

Despite the general advances in smoking control, the high rates of treatment failure in smoking cessation programs constitute a cause for concern. \[[@CR7]\] Among the various complicating factors are high levels of anxiety, depression, and stress, as well as a low level of motivation for change, on the part of patients who seek treatment via smoking cessation programs \[[@CR7]--[@CR9]\].

There is now broad-based recognition employing representative and clinical samples that smokers are more likely to have a psychiatric disorder than non-smokers, and individuals with a psychiatric disorder are significantly more likely to smoke compared to persons without a psychiatric disorder \[[@CR10]\]. Among the various psychiatric disorders implicated in smoking, depressive, and anxiety syndromes (i.e., emotional disorders) are particularly important to study because they are highly prevalent in the general population and remarkably comorbid with smoking \[[@CR11]\]. There is also robust empirical evidence that elevated depressive and anxiety symptoms and emotional disorders increase the risk of smoking experimentation \[[@CR12]\], progression to daily smoking \[[@CR13]\], and development of nicotine dependence \[[@CR14]\] and contribute to maladaptive cognitive--emotional reactions to tobacco \[[@CR15]\].

Smoking incidence and maintenance generalizes across various emotional disorders, including major depression \[[@CR16]\], dysthymia and minor depression \[[@CR17]\], posttraumatic stress disorder \[[@CR18]\], and other anxiety disorders including panic disorder, social anxiety disorder, and generalized anxiety disorder \[[@CR19]\]. A systematic tracking of these disorders in smoking cessation clinic is necessary. Our study is attached in this context aiming to:Measure the frequency of anxio-depressive disorders among smokers of our smoking cessation clinicAssess the relationship between nicotine dependence and the severity of anxiety and depression among the smokersAssess the potential effect of these disorders on the tobacco cessation

Participants and methods {#Sec2}
========================

Type and population of the study {#Sec3}
--------------------------------

This was a cross-sectional study conducted in the smoking cessation clinic in the University Hospital of Sahloul in Sousse, Tunisia. We included in this study the records of all smokers who attended the clinic since the date of its creation in December 2009 until May 2015 (*n* = 534). The monitoring of the smokers was performed by retrieving the records until May 2016 in order to assess their smoking cessation status at 1 year. Some of these records had missing data about the status of smoking. Smokers with incomplete records were contacted in May 2016 by phone to give information on their status. Our clinic activities have begun in December 2009, and all the departments of the hospital were informed of its creation. This preventive clinic is linked to the Department of Prevention and Security of Care. It is open free of charge to the public including hospital staff, hospital patients, and community. It is provided by a team of two physicians specialized in counseling of smokers, two nurses, and a nutritionist when necessary.

Data collection {#Sec4}
---------------

Patients' data were collected using their records of the smoking cessation clinic. These data included:Sociodemographic variables: age, sex, marital, and employment status, educational level, personal history of health problems, and lifestyle habitsCharacteristics of the smoking history: the duration of smoking, number of daily smoked cigarettes, the age of smoking initiation, and previous quit attemptsFagerstrom Nicotine Dependence Test (FTND) \[[@CR20]\] was used to measure the level of nicotine dependence for smokers. FTND consists of six items and scoring for each item may differ from question to question. The cut-off score for FTND scale would be low dependence (0--4), moderate dependence (5--6), and high dependence (7--10).The exhaled carbon monoxide in air (CO) at the first visit \[[@CR21]\]The perceived motivation to quit: assessed by the Lagrue and Legeron test \[[@CR22]\]: smokers having a score equal or above 12 were considered as motivated to quitThe score of perceived self-confidence to quit smoking: assessed by a Likert scale ranging from 0 (not confident at all) to 10 (extremely confident). Smokers having a score ≥ 5 were considered confident to quit.

To measure depression and anxiety, severity was evaluated on the basis of the Hospital Anxiety Depression Scale (HAD) \[[@CR23]\]. Scores of 12 and 8 were respectively considered the threshold for anxiety and depression.

Other addictive behaviors were assessed by the interrogation: evaluation of the consumption of alcohol based on the number of glasses.

The evaluation of the tobacco cessation {#Sec5}
---------------------------------------

The smoking cessation was confirmed by the smoker himself and verified by the measurement of the CO in the expired air.

All patients were contacted and interviewed by telephone, which has allowed us to retrieve the information from the patients who have interrupted the follow-up. Non-responders at the date of the scheduled visit were considered as persistent smokers in the analysis of results.

In our study, successful smoking cessation defined as a complete and continuous abstinence was assessed at 1 week, at 1 month, at 3 months, at 6 months, and at 12 months. An exploratory study of the factors of successful smoking cessation was done in subjects who stopped smoking in about a week and maintained for 1 year or more among smokers who consulted more than twice.

Statistical analysis {#Sec6}
--------------------

The statistical package SPSS 10.0 for Windows (IBM, USA) was used for the analyses. We compared anxiety and depression scores between patients abstinent and patients still smokers. Data were presented with frequencies, means, and standard deviations. Categorical variables were compared using the chi-square statistical method. Odds ratios and 95% confidence intervals were calculated. Differences between means for univariate analyses on continuously distributed variables were compared using Student's *t* test or ANOVA test. Univariate then multivariate analyses were performed in order to identify the determinants of a successful smoking cessation among smokers with anxio-depressive disorders. For all statistical analyses, differences were considered significant at *p* value \< 0.05.

Results {#Sec7}
=======

Population characteristics {#Sec30}
--------------------------

During the study period, a total of 534 smokers were included. The participants were predominantly males (*n* = 500, 93.6%). Their mean age was 42.1 ± 13.8 years old with extremes ranging from 14 to 82 years old. The two age groups most represented were those of 45--54 years old (*n* = 139; 26%) and 25--34 years old (*n* = 129; 24.2%). Almost half of our population (49%) were heavy smokers (more than 20 cigarettes per day) and 48.9%of smokers were strongly addicted to nicotine (Fagerström score ≥ 7) (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of smokers attending the smoking cessation clinic of the University Hospital Sahloul, Sousse, 2009--2015CharacteristicNumber (*n*)Percentage (%)Gender (*n* = 534) Male50093.6 Female346.4Age ≤ 24 years6211.6 25--34 years12924.2 35--44 years9918.5 45--54 years13926 55--64 years8315.5 ≥ 65years224.1Age (mean ± standard deviation)42.1 ± 13.8 yearsEducational level (*n* = 534) Primary15829.6 Secondary19937.3 University17733.1Employment status (*n* = 534) Student417.7 Employee40074.9 Unemployed9317.4Practice of at least 30 min of physical activity per week (*n* = 528\#)24646.6Alcohol intake (*n* = 466)8916.7Medical history of high blood pressure (*n* = 534)438.1Medical history of diabetes mellitus (*n* = 534)6011.2Medical history of coronary heart disease (*n* = 534)326Medical history of respiratory disease (*n* = 534)326.2Medical history of gastric pathologies (*n* = 534)458.4Age of smoking onset (*n* = 528\#) ≤ 12years489 \> 12 years48091Number of daily smoked cigarettes (*n* = 534) \< 2027251 ≥ 2026249Fagerström score (*n* = 534) \< 727351.1 ≥ 726148.9Previous attempt to quit (*n* = 534)28152.6Exhaled CO in air (*n* = 449\#) (mean ± standard deviation)14.86 ± 9.67Score of motivation (*n* = 534) ≤ 1214727.5 \> 1238772.5Score of self-confidence to quit (*n* = 534) ≥ 56011.2 \< 547488.8\# Missing information

The mean number of daily smoked cigarettes was 26.97 ± 14.6 cigarettes with extremes ranging from 1 to 100 cigarettes (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Distribution of the number of cigarettes smoked per day by smokers attending the smoking cessation clinic of the University Hospital Sahloul, Sousse, 2009--2015

The average score of nicotine dependence was 6.26 ± 2.38 with extremes ranging from 0 to 10.

72.5% of smokers were motivated to tobacco cessation. The average score of motivation was 14.36 ± 4.63. The search for a better state of health was the main reason inciting 71% of them to quit smoking (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Distribution of smokers according to the reasons for the decision to quit smoking

The measurement of the exhaled carbon monoxide in air (CO) was performed among 449 smokers. The average rate of exhaled CO in air was 14.86 ± 9.67 ppm (ppm) with extremes ranging from 1 to 60.

The consumption of alcohol was found in 16.7% of smokers. A cardiovascular history was reported in 20.9% in which the most frequent were the high blood pressure (*n* = 43; 8.1%) and coronary artery disease (*n* = 32; 6%). A medical history of respiratory disease was noted in 32 smokers (6.2% of cases). A history of depression has been found in 12 smokers (Table [2](#Tab2){ref-type="table"}).Table 2Description of medical characteristics of smokers attending the smoking cessation clinic of the University Hospital Sahloul, Sousse, 2009--2015Medical historyNumber (*n*)Percentage (%) Cardiovascular history11020.9  Coronary artery disease326  Obliterative arterial disease of the lower limbs101.9  Stroke61.2  Hypertension438.1  Thrombophlebitis122.3  Disorder of the Pace71.4 Respiratory history326.2  Chronic obstructive pulmonary disease61.1  Bronchitis repetition163.1  Lung emphysema10.2  Asthma61.2  Pulmonary tuberculosis30.6 History of depression122.3 Diabetes6011.2 Digestive history458.4

Anxio-depressive disorders and smoking cessation {#Sec8}
------------------------------------------------

We identified 315 smokers (59%) presenting an anxio-depressive disorder among the 534 attendees of the smoking cessation clinic. Based on the HAD scale, we found 231 patients (43.4%) with anxiety disorders (A-HAD scale ≥ 12), 200 (37.6%) with depressive disorders (D-HAD scale ≥ 8), and 116 (21.8%) patients with both anxiety and depression (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Frequency of anxio-depressive disorders at the time of the first consultation (the total does not sum up to exactly 100% because of multiple diagnoses)

The average score of anxiety was 10.67 ± 4.63 and that of depression was 6.49 ± 3.58.

A strong dependency was more common among anxious smokers (46.7%), followed by depressed smokers (43%), and the least was among the anxio-depressed smokers (one quarter). The average score of physical dependence was higher among smokers with an anxio-depressive disorder than among those who are not (6.67 ± 2.35 vs 5.67 ± 2.35) (Table [3](#Tab3){ref-type="table"}).Table 3Anxio-depressive disorders according to Fagerström score among the attendees of the smoking cessation clinic of the University Hospital Sahloul, Sousse, 2009--2015Psychological disorderPercentages (%)Fagerström score*p*Anxiety Yes (*n* = 231)43.46.74 ± 2.36\< 10^−3^ No (*n* = 301)56.65.90 ± 2.34Depression Yes (*n* = 200)37.66.74 ± 2.43\< 10^−3^ No (*n* = 332)62.45.98 ± 2.31Anxio-depressive disorder Yes (*n* = 116)21.86.67 ± 2.350.001 No (*n* = 416)78.25.67 ± 2.35

Anxio-depressed smokers were less likely to experience successful tobacco cessation than non-anxio-depressed ones at 1 week, 1 month, 3 months, 6 months, and at 1 year. These differences were significant only at 1 month (Table [4](#Tab4){ref-type="table"}). We have taken into consideration for the analyses only smokers who had more than two visits to the smoking cessation clinic.Table 4Distribution of smokers according to the time of tobacco cessationTobacco cessation at1 week (%)1 month (%)3 months (%)6 months (%)1 year (%)Not anxio-depressive smokers (*n* = 217)35.969.639.330.425Anxio-depressed smokers (*n* = 315)32.751.234.123.218.3*p* value0.43\< 0.0010.210.060.07Total (*n* = 534)33.958.736.226.121

In the univariate analysis, advanced age and a high number of visits to the clinic were significantly associated with successful cessation at 6 months (Table [5](#Tab5){ref-type="table"}). In the multivariate analysis, only a high number of visits to the clinic was an independent factor associated with smoking cessation at 6 months (*p* = 0.012; OR = 1.23; CI = \[1.04--1.46\]). The univariate as well as the multivariate analyses showed no factor significantly associated with the relapse at 12 months.Table 5Factors associated with a successful smoking cessation at 6 months among smokers with anxio-depressive disorders attending the smoking cessation clinic of the University Hospital Sahloul, Sousse, 2009--2015Smoking cessation at 6 monthsOR \[95% CI\]*p*Yes\
*n* (%)No\
*n* (%)Gender0.66 \[0.15--2.87\]NS Female3 (30)7 (70) Male16 (22.2)56 (77.8)Age (mean ± standard deviation)48.05 ± 10.4941.31 ± 13.271.04 \[1--1.09\]0.05Previous attempt to quit1.08 \[0.36--3.25\]NS Yes13 (23.6)42 (76.4) No6 (22.2)21 (77.8)Mean number of daily smoked cigarettes24.63 ± 14.3629.05 ± 15.860.97 \[0.94--1.01\]NSMean number of visits to the clinic6.74 ± 3.144.48 ± 2.861.23 \[1.04--1.46\]0.012\*Score of perceived self-confidence to quit1.7 \[0.33--8.54\]NS ≥ 517 (25.4)50 (74.6) \< 52 (16.7)10 (83.3)Score of motivation0.67 \[0.21--2.09\]NS \> 1213 (21.3)48 (78.7) ≤ 126 (28.6)5 (71.4)Fagerström score1.01 \[0.36--2.82\]NS \< 79 (23.1)30 (76.9) ≥ 710 (23.3)33 (76.7)*NS* not significant\**p* \< 0.05

Discussion {#Sec9}
==========

The tobacco use may alter the function of the serotoninergic neurons by the intermediary of at least two of these compounds: nicotine and the bêtacarbolines. This finding reinforces the hypothesis that some psychiatric disorders are probably associated with the consumption of tobacco, because those several compounds of tobacco entail sustainable disturbances in the neurobiological cerebral functioning, including those of the serotonergic system \[[@CR24]\]. This study was conducted to assess the effect of psychological problems (depression and anxiety) on the tobacco cessation among smokers attending the smoking cessation clinic of the University Hospital of Sahloul of Sousse.

The existence of an association between anxio-depressive disorders and smoking is clearly established. Depression is the psychiatric comorbidity the better documented. In fact, the prevalence of smoking is higher among patients with major depression. Similarly, the percentage of major depressive disorder was two times higher in smokers versus non-smokers. Thus, the risk of major depressive episode is increased during the 6 months following the smoking cessation \[[@CR25]\]. In our study, the prevalence of anxio-depressive disorder was comparable to that found in the study of Fakhfakh et al. in Tunisia (47.2%) \[[@CR6]\] using the HAD scale to identify anxio-depressive disorders. It is also comparable to that found by Lasser et al. (55.3%) \[[@CR26]\] where rates of smoking and tobacco cessation were studied according to the number and type of psychiatric diagnosis, assessed by a modified version of the Composite International Diagnostic Interview.

Smokers with comorbid depressive disorders are more prone to become dependent on nicotine, to progress to a more severe level of dependence, and to experience more severe nicotine withdrawal symptoms than smoker without depressive disorders \[[@CR27]\]. In addition, it has long been recognized that the consumption of tobacco allowed some smokers to control their anxiety as a self-medication. It also seems that smoking cessation can be accompanied by an improvement of the anxiety \[[@CR25]\].

Based on the scores of the HAD scale revealed during the first consultation, we have noted 43.4% of anxiety disorder among smokers and 37.6% of depressive disorder with average scores of 10.67 and 6.49 respectively for the anxiety and depression. In the study conducted by Fakhfakh et al. in Tunisia, among 70 patients who responded to the HAD test, they found 22.9% having a depressive disorder and 20% patients with anxiety disorders \[[@CR6]\]. The presence of a note of anxiety was significantly higher among women than among men. This difference was not significant in our study, which can be explained by the small size of the sample.

Some research has indicated that smoking helps calm some of the symptoms like restlessness, agitation, and irritability in major depression disorder. Perhaps these smokers are attempting to use smoking as a way to relieve themselves of the symptoms of their depression which could make it extremely difficult for the person to quit smoking. Research has indicated that having this diagnosis does present a challenge for quitting smoking. Among smokers on a Quitline in California, smokers with current major depression were much less likely to have quit for at least 30 days at the time of the 2-month evaluation, compared to those with minimal depressive symptoms \[[@CR28]\]. In our study, 55.2% of smokers with anxio-depressive disorders have tried at least once to stop smoking. We did not find a significant difference in the attempts to quit between depressed subjects, anxious, anxio-depressed, and normal subjects. According to the study conducted by Fakhfakh et al. \[[@CR6]\], three quarters of patients have made at least one attempt to quit smoking. However, the difference with smokers without anxio-depressive disorder was not significant. According to another study conducted by Mumtaz et al. on 1725 participants \[[@CR29]\], the rate of previous attempts to stop was significantly higher among weakly dependent smokers. In our study, the mean score of motivation was 4.36 ± 4.63. This score was similar among both smokers not presenting an anxio-depressive disorder and anxio-depressed smokers.

According to Mendelsohn \[[@CR30]\], contrary to popular belief, evidence suggests that smokers with depression are highly motivated to quit smoking. In fact, in a study conducted by Haukkala et al. \[[@CR31]\], female smokers who were depressed were more motivated to quit than those with a lower depression score. The mean score of self-confidence to quit was 6.57 ± 2.41 in anxious smokers, 6.33 ± 2.48 in depressed smokers, and 6.14 ± 2.65 in anxio-depressed smokers. On the contrary, in the study of Fakhfakh et al., subjects with a history of depression had significantly a lower mean score of self-confidence to quit \[[@CR6]\]. Zvolensky et al. \[[@CR10]\], in their survey on more than 3000 subjects, have shown that depression is more common among smokers than non-smokers and that smokers with a history of depression were significantly less likely to quit smoking.

Furthermore, in our study, anxiety and depression were not correlated to the number of cigarettes smoked per day, nor to the average rate of exhaled CO in air. Our findings were in line with those of Zvolensky et al. \[[@CR10]\].

The mean Fagerström score was of 6.26 ± 2.38. It was significantly higher among smokers with an anxio-depressive disorder during the first consultation. This score was 7.32 in the study of Fakhfakh and it was also significantly higher among smokers with an anxio-depressive disorder \[[@CR6]\].

Strongly dependent smokers with anxio-depressive disorder are frequently encountered in the smoking cessation clinic. Hence, in a study by Largue et al. \[[@CR32]\] on 517 smokers, a frequency of 34% of strongly dependent anxio-depressive smokers was found with variable intensities of depression. The association between smoking and major depression is stronger if there is a dependency to nicotine \[[@CR10]\]. The results found by Mumtaz et al. \[[@CR29]\] confirmed that the symptoms of depression, anxiety, or agoraphobia were more severe in smokers strongly dependent than among non-dependent ones. These conclusions were in line with those of Coutino et al. \[[@CR33]\] and Pedersen and Von Soest \[[@CR34]\], where heavy smoking and a strong dependence to nicotine were associated with a high rate of depression and anxiety.

Tobacco cessation is a difficult process because of the multiple dependencies (pharmacological, behavioral, and psychological). Among the objectives of our survey was to estimate the impact of the anxio-depressive disorder among smokers of the smoking cessation clinic. We have defined tobacco cessation as a total abstinence for a duration equal to or more than a week. About one third (33.9%) of our participants succeeded in the withdrawal. For the same definition, a study made at the Institute Salah Azzaiez among smokers in their smoking cessation clinic in 2004 \[[@CR35]\] found a rate of withdrawal of 27%. Our rate could be explained by the strong dependency found in more than half of the smokers as well as the high number of people dropped out and had been counted as a failure in the analysis. In addition, 74.1% of smokers have benefited of only one or two visits.

The rate of tobacco cessation among smokers with anxio-depressive disorder of our study varied according to the duration maintained of tobacco cessation; it was 51.2% at 1 month which decreased gradually to reach 18.3% at 12 months.

In our study, the follow-up to the consultation was the predictive factor of successful tobacco cessation at 6 months. On the other hand, in multivariate analysis, no factor appeared as a predictive factor of relapse at 1 year. This finding was different from that found in the study by KesKesBoudawara et al. \[[@CR36]\] and by Underner et al. \[[@CR37]\], where only a follow-up prematurely interrupted was significantly associated with the relapse.

Tobacco use is often considered as a tool to overcome difficult situations caused by social anxiety and lack of confidence in smokers suffering from anxio-depressive disorders. These disorders are more frequent among women, explaining in part their greater difficulty to stop smoking. The other reasons are the greater frequency of depressive disorders, the less effectiveness of nicotine substitutes, and the more important fear to gain weight once stopping smoking among women \[[@CR38]\]. Furthermore, smokers would find in the consumption of cigarettes a way to reduce the negative emotions including the negative symptoms of withdrawal \[[@CR23]\].

Sonntag et al. \[[@CR39]\] have highlighted through a longitudinal study on 3021 adolescents and young adults, an association between social phobia, and anxiety disorders and the occurrence of a nicotinic dependency. The recognition of the importance played by the negative emotions in the smoking behavior has led some authors to suggest the use of antidepressants and anxiolytics as a treatment for tobacco dependence \[[@CR40]\]. Furthermore, some smokers who are trying to quit could be helped by concurrent treatment for depression.

Study limitations {#Sec10}
-----------------

The present study has some limitations with regard to the generalizability of the findings. First, the sample size was small particularly the number of anxio-depressed smokers compared to many other studies. Second, for some variables, we did not have the necessary information which diminished further our sample size. Finally, perhaps going further with the study may increase the sample size.

Conclusion and recommendations {#Sec11}
==============================

The association of anxio-depressive disorder with tobacco use is very frequent, since it is found in more than 50% of the strongly dependent smokers attending the smoking cessation clinics. These disorders are more severe as the level of dependency is higher. Our findings did not conclude on the association between anxio-depressive disorder and smoking dependence. However, we found that the rate of anxio-depressive disorder among smokers seeking for tobacco cessation was high among our population study. We recommend to systematically assess the presence of anxio-depressive disorder among smokers attending smoking cessation clinics so we will not miss the presence of such disorder that may delay tobacco cessation.
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